Andera Partners

EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, aimed at treating disorders related to spinal cord injuries. The company utilizes HSV-1-based vectors, leveraging the natural characteristics of the Herpes Simplex Virus 1 to establish lifelong latency in peripheral neurons. This innovative approach allows for targeted and sustained expression of therapeutic genes, providing a potential cure for severe, chronic, and localized conditions, such as neurogenic bladder disorders resulting from spinal cord injuries. By focusing on this advanced gene therapy technique, EG 427 seeks to improve treatment outcomes for patients suffering from these debilitating conditions.

Ayming is a management consulting firm headquartered in Levallois, France, that focuses on optimizing operational performance for its clients. The company provides a range of services, including consulting on human resources costs, tax strategies, operational costs optimization, software solutions, and energy and environmental issues. Additionally, Ayming offers advisory services related to work contributions and wage audits. By leveraging these diverse consulting offerings, Ayming aims to help organizations enhance their efficiency and overall performance while effectively managing social costs associated with taxes and financial operations.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Qovoltis operates in the renewable energy sector, focusing on innovative charging solutions for electric vehicles. The company offers a smart charger that adapts to real-time power demand and is compatible with vehicles adhering to the ISO 15118 standard. Additionally, Qovoltis provides a mobile application that enables users to authenticate and manage their charging remotely. The company caters not only to individual users but also to real estate projects by offering advanced charging station solutions that enhance asset value. Their services include the installation of delivery points, terminal connections, real-time terminal supervision, and the provision of electricity at competitive rates, allowing customers to effectively manage and optimize their charging experiences.

Skysun is a financial institution that provides financial solutions and services to the solar energy sector.

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

SciRhom GmbH is a biotech company focused on the preclinical and early clinical development of novel biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Founded in 2016 through collaboration between academic and industry scientists with expertise in antibody development, SciRhom leverages extensive research and a network of specialists to advance its therapeutic offerings. The company develops therapeutic antibodies targeting iRhom2, a significant modulator of key pro-inflammatory signaling pathways, including TNF-alpha. This approach seeks to enhance treatment options for patients suffering from severe autoimmune conditions, particularly those affecting the skin and intestinal barriers.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Mylight150 contributes to the creation of a society in which people generates own electricity to ensure self-sufficiency and long-term abundance.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Qualisteo SAS, founded in 2010 and based in Nice, France, specializes in energy efficiency monitoring through its software tool, Wattseeker. This technology is designed to audit electrical consumption across entire buildings, providing detailed insights by usage, equipment, and zone. By enabling enterprises to measure and control their electricity consumption, Qualisteo helps optimize their environmental footprint and reduce electricity costs. The company offers installation services and valuable reports on electrical consumption, contributing to energy savings and more informed decision-making for industrial sites.

Kepler Consulting is a business management consulting firm that serves various industries, including automotive, capital goods, aviation, and consumer products. The company focuses on enhancing productivity and maximizing operating profits for its clients through expertise in innovation, purchasing, supply chain management, marketing, sales, and operations. By offering tailored solutions, Kepler Consulting aims to improve efficiency and optimize operating margins for a diverse range of clients, including those in the public sector, luxury, retail, distribution, and service sectors, as well as in the automotive and cosmetics industries.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

BioVentrix, Inc. is a medical device company based in San Ramon, California, that specializes in innovative treatments for congestive heart failure (CHF), particularly in patients with ischemic cardiomyopathy. Founded in 2003, the company has developed the Revivent Myocardial Anchoring System, which utilizes a hybrid closed-chest transcatheter procedure to enhance cardiac function. This device operates by restoring the size and volume of the left ventricle through the implantation of micro-anchoring pairs that effectively exclude scarred myocardium from healthy tissue. BioVentrix aims to provide less invasive, catheter-based solutions to improve patient outcomes and slow the progression of CHF, addressing a critical need in cardiac care.

Andera Partners, established in 2001, is a Paris-based private equity firm with a 250-year heritage tracing back to the Rothschild family. The firm manages over €2 billion, focusing on investments in unlisted companies across France and internationally. Andera Partners specializes in life sciences, growth capital, and sponsorless mezzanine debt, aiming to create long-term value for its investors.

Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

SoniVie is engaged in the development of a medical device aimed at treating pulmonary hypertension through advanced denervation techniques. The company’s device involves a catheter that is inserted into the pulmonary artery during a minimally invasive procedure. This device selectively targets and damages the nerves linked to the disease without affecting the vessel walls or surrounding tissues, allowing physicians to effectively address the condition.

Senstronic is an automotive company that specializes in the design and manufacture of detection-based solutions and connectors for various applications, including automotive, aeronautics, and high-resistance environments like railways and agricultural machinery. The company's product range includes various types of sensors, such as inductive, magnetic, capacitive, and optic-electronic proximity sensors, as well as splitting systems. By addressing complex challenges faced by clients, Senstronic aims to enhance operational efficiency and increase return on investment for its customers.

Qovoltis operates in the renewable energy sector, focusing on innovative charging solutions for electric vehicles. The company offers a smart charger that adapts to real-time power demand and is compatible with vehicles adhering to the ISO 15118 standard. Additionally, Qovoltis provides a mobile application that enables users to authenticate and manage their charging remotely. The company caters not only to individual users but also to real estate projects by offering advanced charging station solutions that enhance asset value. Their services include the installation of delivery points, terminal connections, real-time terminal supervision, and the provision of electricity at competitive rates, allowing customers to effectively manage and optimize their charging experiences.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Resonance Imaging Group operates medical imaging centers in Franconville, France, focusing on providing access to various imaging services for accurate diagnoses. The company specializes in several areas, including neuroimaging, oncology imaging, chest imaging, thyroid imaging, urinary imaging, virtual colonoscopy, and visceral imaging. Through its network of centers and advanced imaging technology, Resonance Imaging aims to enhance diagnostic precision and improve patient outcomes.

HR Path is a global consultancy focused on human capital management, with a team of over 500 consultants operating across North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting, offering a range of services to support businesses in their digital transformation. HR Path is an authorized reseller of various HR software solutions, including those from SAP, SuccessFactors, and Oracle HCM, among others. In addition to reselling, the company has developed its own HR software solutions, such as BiHRdy, a business intelligence tool; Pandore, a packaged HR, payroll, and time management solution; and Geef, a talent management system. The client portfolio includes a mix of large corporations, including CAC 40-listed companies, as well as small and medium-sized enterprises and public sector organizations, reflecting its versatility in meeting diverse client needs.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

ERI is a provider of electrical and technical engineering services, serving both private and public project owners in the construction and industrial sectors. The company specializes in the installation of various electrical and telecommunications equipment, including high and low-voltage systems, technical cabling, and optical fibers. In addition to its installation services, ERI offers expertise in climate engineering, as well as construction, renovation, and routine maintenance. This comprehensive approach allows ERI to support its clients across all facets of the construction industry, ensuring that their technical needs are met with precision and reliability.

Kyotherm is an investment company that focuses on financing renewable heat production and energy efficiency projects. The company provides equity investment services to energy service providers, engineering firms, developers, heat consumers, and equipment manufacturers, assisting them in securing third-party financing for their initiatives. Kyotherm specializes in acquiring majority stakes in green energy generation projects, including geothermal and biomass heating plants, as well as district heating networks. By facilitating project capital, Kyotherm enables clients to develop diverse energy infrastructures while enhancing the contractual and financial structuring of these projects.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

Lhyfe is a company based in Nantes, France, that specializes in the design, development, and operation of industrial sites for the production of green hydrogen using renewable energy sources such as wind and solar power. Founded in 2017, Lhyfe aims to provide substantial quantities of clean and affordable hydrogen, facilitating the transition of various industrial sectors and transportation towards a sustainable energy framework. The company focuses on two primary markets: heavy mobility, including trucks, buses, trains, and potentially maritime and air transport, as well as industrial applications, targeting industries such as chemistry, steel, and glass production. By integrating its production facilities with available renewable energy sources, Lhyfe ensures a minimal environmental footprint while addressing the urgent need to reduce greenhouse gas emissions.

ImmoCity provides real estate investment and management services for both individuals and institutions or private companies. Their services include asset management, compelling investment opportunities, investment discipline, alignment of interests, strategic and institutional risk management compliance, and enabling clients to access proper mediums for their investment and expansion.

Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing treatments for dementia and other neurological conditions. The company specializes in a targeted drug rescue program aimed at repurposing approved medications for new therapeutic indications. Exciva's approach includes the creation of symptomatic and disease-modifying therapies, alongside other formulations designed to address both neurological and psychological aspects of behavioral symptoms. By enabling the healthcare industry to access its innovative program, Exciva aims to improve treatment options and outcomes for patients suffering from various conditions, particularly those associated with dementia.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

MC2-Technologies specializes in the development of innovative equipment designed to protect sensitive sites and infrastructures. The company focuses on manufacturing advanced microwave amplifiers and employs expertise in microwave frequencies and nanotechnologies. Its offerings include the characterization, modeling, and design of microwave components and devices. By serving clients in the defense, security, and telecommunications sectors, MC2-Technologies enables effective protection solutions tailored to the needs of these industries.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Sogetrel, S.A.S. is a prominent company specializing in the design, deployment, and maintenance of network infrastructures and digital communication solutions. Established in 1985 and headquartered in Issy les Moulineaux, France, Sogetrel operates branches in Belgium and Switzerland. The company provides a range of services, including the integration of telecommunications networks, IP security systems for video surveillance and access control, and support for smart city projects. Sogetrel serves a diverse clientele across various sectors such as telecommunications, public authorities, defense, transport, and utilities. By focusing on the development of very high-speed networks and offering both customized and turnkey solutions, Sogetrel aims to enhance the quality of life for citizens while promoting efficiency and sustainability in the regions it serves.

Sirsa, founded in 2014 and based in Paris, France, is a consulting firm focused on sustainable transformation. The company specializes in evaluating existing processes, analyzing risks, and defining strategies to enhance operational sustainability. Sirsa provides a software-as-a-service platform for measuring companies' extra-financial footprint and impacts. It assists clients in implementing strategic initiatives, managing action plans, reporting results, and ensuring compliance with regulations. The firm serves a diverse range of industries, including aerospace, defense, food products, electrical equipment, healthcare, energy, medical supplies, environmental services, and software, among others.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

MasterGrid, based in Grenoble, France, specializes in the manufacture and supply of high voltage electrical equipment tailored for the commercial and industrial sectors. Established in 2019, the company produces a range of products including high, medium, and low-voltage equipment designed for the distribution, protection, control, and management of electrical systems. In addition to manufacturing, MasterGrid offers equipment handling services, ensuring that clients receive safe and durable products that enhance performance and efficiency.

Olaqin is a healthcare service provider based in Suresnes, France, specializing in e-health solutions for healthcare professionals. The company distinguishes itself by offering tailored services to various sectors within the healthcare industry. Olaqin operates through a value-added distribution network, supplying SESAM-Vitale readers and associated software indirectly, while also engaging directly with hospitals and pharmacies via public and service contracts. Its offerings include centralized payment systems, securing electronic care sheets, updating Vitale cards, and ensuring secure access to online medical records. These services enhance operational efficiency for healthcare professionals by providing essential technological and management support.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Ellisphere is a business intelligence company that provides decision-making information to executives and decision-makers in France and internationally through its BIGnet network. The company offers a comprehensive platform that delivers economic and financial information about trading partners, as well as insights into customer and supplier portfolios. Additionally, it provides guidance on legislation and regulatory compliance, helping businesses to develop effective customer-base strategies. By focusing on information management and data marketing, Ellisphere supports organizations in promoting and sustaining their growth and development.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

99 Advisory is a banking and insurance sectors are facing radical changes in their environments.

Travelsoft is a company focused on developing software solutions for the travel industry. It offers a Software-as-a-Service platform called Orchestra, which enables tourism professionals to create, manage, distribute, and administer leisure travel packages. The platform facilitates the distribution of various travel components, including journey packages, hotels, and flights, allowing users to manage their offerings across multiple distribution channels effectively. Through its innovative tools, Travelsoft aims to enhance the operational efficiency and reach of travel professionals in the leisure sector.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

SPHEREA specializes in the design and production of modular testing solutions for various electrical applications, catering to manufacturers, equipment suppliers, integrators, and rail operators. The company offers a range of products including model-based testing systems, field test equipment, wiring testers, and assisted maintenance and repair solutions. SPHEREA's expertise spans the entire life cycle of complex electronic, microwave, optronic, and mechatronic systems, serving critical sectors such as civil aeronautics, defense, energy, and rail both in France and internationally.

HR Path is a global consultancy focused on human capital management, with a team of over 500 consultants operating across North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting, offering a range of services to support businesses in their digital transformation. HR Path is an authorized reseller of various HR software solutions, including those from SAP, SuccessFactors, and Oracle HCM, among others. In addition to reselling, the company has developed its own HR software solutions, such as BiHRdy, a business intelligence tool; Pandore, a packaged HR, payroll, and time management solution; and Geef, a talent management system. The client portfolio includes a mix of large corporations, including CAC 40-listed companies, as well as small and medium-sized enterprises and public sector organizations, reflecting its versatility in meeting diverse client needs.

Tournus Equipement, S.A.S. is a manufacturer based in Tournus, France, specializing in stainless steel environments for professional kitchens and supermarket fish counters. The company provides a wide range of products, including mobile and modular kitchens, regeneration ovens, warmers, sterilizing cabinets, and various kitchen units. It also designs and manufactures equipment such as trolleys, containers, wash-basins, dishwashing equipment, and shelving products. Tournus Equipement serves diverse sectors, including canteens, restaurants, bakeries, supermarkets, and transport catering services. In addition to its manufacturing capabilities, the company offers joint design, installation, and express delivery services, catering to the specific needs of its clients. Founded in 1910, Tournus Equipement is known for its commitment to quality and durability in commercial kitchen solutions.

Verbraeken Infra NV is a Belgian company specializing in the construction and renovation of underground and overhead infrastructure networks across Europe and North Africa. Founded in 1966 and based in Temse, Belgium, the company provides a wide range of services, including earth and roadworks, pipeline and sewer installation, and electrical works such as the installation of underground transmission cables and public lighting maintenance. Verbraeken Infra also engages in the installation of traditional copper and coaxial cables, as well as advanced techniques like horizontal directional drilling and pipe jacking. With approximately 1,000 employees and annual sales of €140 million, the company has expanded its operations in France, Germany, and the Benelux region, strengthening its market position in Belgium and enhancing its capacity to serve gas, water, electricity, and telecom companies.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Lease Protect France SAS is a company based in Marseille, France, specializing in the installation, servicing, and maintenance of video surveillance and security systems. Founded in 2009, it offers a variety of products, including anti-theft gates, closed-circuit televisions, fog generators, and electronic plotters. The company focuses on addressing shrinkage concerns, particularly for small and medium-sized businesses, by providing tailored solutions that leverage advanced technology. Its extensive network includes offices in multiple locations across France, allowing for local proximity and responsive service. Additionally, Lease Protect offers innovative financing solutions to support its clients in implementing effective security measures.

Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing treatments for dementia and other neurological conditions. The company specializes in a targeted drug rescue program aimed at repurposing approved medications for new therapeutic indications. Exciva's approach includes the creation of symptomatic and disease-modifying therapies, alongside other formulations designed to address both neurological and psychological aspects of behavioral symptoms. By enabling the healthcare industry to access its innovative program, Exciva aims to improve treatment options and outcomes for patients suffering from various conditions, particularly those associated with dementia.

Solware Group is a software publisher and integrator focused on providing innovative and scalable solutions for the medico-social and automotive sectors. The company develops robust enterprise software tailored to the specific needs of medical facilities and auto garages, enhancing operational efficiency and addressing daily challenges faced by its clients. By delivering adaptable software, Solware Group aims to improve the business operations of its users, ensuring that they can effectively navigate the complexities of their respective industries.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Bioclinic operates a network of medical analysis laboratories in the Ile-de-France region, serving health professionals, hospitals, clinics, care centers, and retirement homes. Founded in 1995 and based in Paris, the company specializes in areas such as molecular biology, genetics, antibiotic resistance, and reproductive health. By focusing on these fields, Bioclinic aims to provide clients and their patients with enhanced medical diagnostic results.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Groupe JORYF is a specialist in housing construction located in Ile-de-France. The company provides a range of construction and engineering services tailored for the housing market. Its offerings include in-house structural work, masonry, and the development of various types of housing such as collective housing, single-family homes, and offices. Additionally, Groupe JORYF engages in the construction of tourist hotels, student housing, and residences for the elderly, demonstrating its versatility and commitment to meeting diverse housing needs.

Platinum Invest group specializes in jewelry production for luxury brands.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Skill & You is the leading provider of vocational e-learning in France, focusing on delivering real results and recognized qualifications such as BAC PRO, BEP, BP, BTS, and CAP. The company operates an online education and distance learning platform that offers customized courses tailored to the specific needs of learners and industries. By leveraging innovative pedagogy and adaptable educational technology, Skill & You empowers individuals to acquire professional skills necessary for career advancement or personal development. With a strong track record of successful educational initiatives, Skill & You is committed to addressing the challenges of employment by equipping learners with the skills needed to transform their lives.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

Orbility is a developer of off-street parking applications and programs aimed at enhancing transportation systems. The company provides a range of solutions, including automated fare-collection systems, real-time passenger information systems, and vehicle tracking and management tools. These offerings enable clients, which include airports, shopping centers, municipalities, and both public and private operators, to gain complete operational and management control over their parking systems. By focusing on improving the efficiency and effectiveness of public transport systems, Orbility aims to streamline parking operations and enhance overall user experience.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

BIOGROUP-LCD, a major French player in local medical biology, supports more than 20,000 patients every day and offers more than 2000 routine and specialized daily examinations, based on performance and technological innovation. Partner at every moment between the patient and the medical profession, your laboratory participates in the screening, diagnosis, monitoring and prognosis of the most common pathologies to the most demanding, throughout your course of care. BIOGROUP-LCD develops for this purpose all its human and technological resources. The team of qualified, qualified medical biologists follows continuous and regular training.

The WALOR Group is a prominent European leader in the mechanical parts market, with 12 production sites across five countries and a workforce of 1,600 employees. The company specializes in the design, production, and assembly of high-precision mechanical parts and sub-systems, primarily through cold forging and machining processes. Its product offerings include forgings and machined components for critical applications such as engines, gearboxes, and steering systems. WALOR serves major manufacturers, system operators, and automotive suppliers, helping them meet their quality, cost, and capacity requirements in the automotive and energy sectors.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

TimeOne, established in 2016, is a global marketing services group formed by merging Public-Idées and Place des Leads. Headquartered in France with operations across Europe, Asia, South Africa, and South America, the company specializes in providing comprehensive digital marketing solutions. TimeOne's core offerings include programmatic advertising, native content marketing, performance-based campaigns, digital marketplace management, publishing services, and mobile marketing strategies. The company is renowned for its innovative approach to prescriptive marketing, driven by a robust data management platform (DMP) and a strong focus on research and development.

GLOBE Groupe sa is a Paris-based advertising agency that specializes in strategic marketing and communication services. The company focuses on shopper marketing to create impactful consumer experiences that drive sales. It offers a range of services including strategic planning, non-media planning, talent casting, recruitment, training, payroll, and logistics such as storage, dispatch, and cold-chain management. GLOBE Groupe also implements marketing activation campaigns and provides tools for performance measurement, utilizing key performance indicators to assess the effectiveness of its strategies. The firm caters to various sectors including consumer goods, media, retail, and recruitment, ensuring that its clients can adapt to the evolving landscape of consumer behavior and promotional messaging. Through its secure online platform, myGLOBE, clients can monitor operations in real-time, enhancing transparency and communication throughout the marketing process.

La Vie Saine is a retailer based in Montgolfier, France, specializing in organic products since its founding in 1952. The company offers a diverse range of items, including dairy products, fruits and vegetables, specialized foods such as eggs and poultry, grocery items, bakery products, hygiene products, and wine. In addition to food, La Vie Saine provides certified ecological cosmetic products for babies and children, as well as organic cosmetics, grains, cereals, and food supplements. The company is committed to ensuring quality by sourcing products made from natural ingredients. Its headquarters are located in Dijon, France.

Loyalty Company is a marketing and communication consultancy that focuses on enhancing business performance through the integration of data and technology. The firm specializes in customer marketing, sales promotion, and branding services, utilizing a combination of data-driven insights, creative strategies, and technological expertise. By prioritizing customer-centric approaches, Loyalty Company aims to help clients build profitable and enduring relationships with their customers, ultimately driving brand strength and business success.

Allodiagnostic SAS, based in Paris, France, specializes in providing essential real estate diagnostics, including assessments for termites, electrical systems, and energy performance. Founded in 2001, the company caters to private individuals during the sale or rental of properties. It serves as a key resource for both consumers and real estate professionals, offering tailored solutions to meet various diagnostic requirements. As of July 2017, Allodiagnostic operates as a subsidiary of Edmond de Rothschild (France).

Intech is a leading manufacturer of orthopedic instruments and implants dedicated to enhancing patient outcomes. Operating with a workforce of around 1,000 employees globally, the company provides comprehensive manufacturing solutions to medical device original equipment manufacturers (OEMs). Intech specializes in a wide range of surgical tools, including implants, sterilization cases, and trays, catering to various medical fields such as spine, hip, knee, sports medicine, and trauma surgery. With facilities located in the United States, France, and Malaysia, Intech is positioned as a one-stop shop for medical device OEMs, delivering both off-the-shelf and custom-made instruments efficiently and cost-effectively.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

Sarawak Group is a media and marketing services company based in Boulogne-Billancourt, France. It specializes in establishing sales, merchandising, and brand activation services aimed at enhancing the performance of its clients' products and services. The company provides a range of offerings, including business-to-business sales, retail sales force support, point-of-sale solutions, event animation, and brand promotion. Its clientele includes small shops, large department stores, and retail companies, reflecting its capability to cater to diverse market needs. Through these services, Sarawak Group seeks to drive sales results and improve brand visibility for its customers.

Studia as a reference in the fields of enterprise content management and document engineering in a complex environment.

Groupe 3S SAS, founded in 2001 and based in Roissy-en-France, France, specializes in providing a comprehensive range of ground handling and airport management services. The company offers essential services to airlines and airport operators, including passenger and baggage handling, load control, ramp activities, and crew management. Additionally, Groupe 3S delivers airport services such as assistance for persons with disabilities, management of taxi areas, cleaning of airports, aircraft de-icing, and runway maintenance. The organization also engages in industrial cleaning, ultra-cleanliness, facility management, and home support services for individuals. Moreover, it provides aviation security training, dangerous goods handling, and ground handling training courses. Through the synergy of expertise from its subsidiaries, Groupe 3S has established itself as a prominent player in the global services market.